Table 3.
Maximum achievable QALYs gained, i.e., with the most effective vaccination strategy at 100% coverage | Vaccination strategy | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
TIV 18–49 years | QIV 18–49 years | TIV 50–64 years | QIV 50–64 years | Adj TIV 50–64 years | QIV 65 years+ | QIV CCD 65 years+ | Recom QIV 65 years+ | TIV HD 65 years+ | Adj TIV 65 years+ | ||
# vaccinees | 1,371,807,436 | 1,371,807,436 | 620,921,647 | 620,921,647 | 620,921,647 | 580,675,667 | 580,675,667 | 580,675,667 | 580,675,667 | 580,675,667 | |
Age groups and QALYs gained | Maximum achievable QALYs by vaccination strategy at 100% coverage | ||||||||||
18–49 years | 636,318 | 609,632 | 636,318 | ||||||||
50–64 years | 1,212,329 | 1,019,832 | 1,064,483 | 1,212,329 | |||||||
65–99 years | 5,363,847 | 4,476,302 | 4,476,302 | 5,362,494 | 5,032,342 | 5,363,847 | |||||
Total QALYs gained for 18–99 years | 7,212,494 | ||||||||||
Relative maximum achievable QALYs vs. 18–99 years | 8.45% | 8.82% | 14.14% | 14.76% | 16.81% | 62.06% | 62.06% | 74.35% | 69.77% | 74.37% | |
Vaccination cost | $52,608,815,160 | $53,047,831,345 | $23,812,131,251 | $24,011,040,080 | $42,820,030,302 | $22,454,728,035 | $26,516,585,100 | $33,891,769,276 | $39,393,300,421 | $40,062,669,268 | |
Relative QALY gain per $10 billion invested | 1.61% | 1.66% | 5.94% | 6.15% | 3.93% | 27.64% | 23.41% | 21.94% | 17.71% | 18.56% | |
Relative QALY gain per 100 million vaccinees | 0.62% | 0.64% | 2.28% | 2.38% | 2.71% | 10.69% | 10.69% | 12.80% | 12.02% | 12.81% |
Bold numbers show the relative QALY gain per US dollar invested and per vaccinated person highest for that age group
Adj adjuvanted, CCD cell culture-derived, HD high-dose, Recom recombinant, QIV quadrivalent influenza vaccine, TIV trivalent influenza vaccine, QALY quality-adjusted life year